At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 84 enrolled
Drug / intervention
Veldona,biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study, Evaluation of Low Dose Natural Human Interferon Alpha Administered by the Oral Mucosal Route in the Treatment of Behçet's Disease
In Brief
A Phase 2 clinical trial evaluating Veldona, for Behcet Syndrome and 2 related conditions. Completed, enrolled 84 participants across 4 sites.
Detailed Summary
The purpose of this study is to determine the safety and efficacy of natural human interferon alpha (IFN alpha) on size, number, incidence and pain of oral ulcers associated with Behçet's Disease (BD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBehcet Syndrome, Behcet Disease, Mucocutaneous Ulceration
CountriesTurkey (Türkiye)
CollaboratorsAinos, Inc. (f/k/a Amarillo Biosciences Inc.
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2006
First PostedJun 2007
Primary CompletionApr 2008
TodayJul 2026
First PostedJun 6, 2007
Enrollment StartApr 1, 2006
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 19.1 years ago
Interventions
Veldona,biological
Very low dose oral natural human interferon alpha lozenges